rethinkTHC Search
Menu
Study breakdown

Review Finds Insufficient Evidence for Cannabis in PTSD, While Polish Clinics Market It Aggressively

ReviewModerate evidence
The takeaway

A literature review found no solid evidence to recommend cannabis for PTSD treatment, yet analysis of Polish medical marijuana clinic websites revealed aggressive marketing of cannabis as a PTSD therapy, highlighting a gap between evidence and commercial claims.

Clinicians treating PTSD, patients considering cannabis for PTSD, and policymakers overseeing medical cannabis marketing.

No sufficient solid evidence to recommend cannabis for PTSD

What the researchers found

The literature review concluded there is currently no sufficient solid evidence to recommend medical marijuana or cannabinoids to treat PTSD. However, people with PTSD use cannabis for its anxiolytic, sedative, hypnotic, and antipsychotic effects. Polish clinic websites were found to market cannabis as a PTSD treatment despite the weak evidence base.

Why it matters

The disconnect between evidence and marketing is a public health concern. PTSD incidence in Poland has increased significantly, creating a vulnerable population that may be targeted by clinics overpromising on cannabis benefits.

The numbers in context

PTSD incidence rising in Poland. No RCTs with sufficient evidence to recommend cannabis for PTSD. Polish clinics actively marketing cannabis as PTSD alternative therapy.

How the study worked

Two-part study: systematic literature review of cannabis/cannabinoid efficacy and safety for PTSD, plus content analysis of websites from Polish clinics specializing in medical marijuana treatment.

What this study cannot tell us

Website analysis reflects a single country (Poland). The literature review may not capture the most recent trials. Patient outcomes from Polish clinics were not directly measured.

How to read the evidence

Combines literature review with novel website content analysis, providing a useful evidence-practice gap assessment.

When this study was published

2025 review with current literature and real-time clinic website analysis.

The bigger picture

This study captures a global pattern: medical cannabis clinics market aggressively while evidence lags behind. The gap between patient desperation and commercial incentives deserves scrutiny, especially for conditions like PTSD where conventional treatments also have limitations.

Questions still open

  • Will ongoing RCTs provide stronger evidence for cannabis in PTSD?
  • Should medical cannabis marketing be regulated more strictly for psychiatric conditions?

Common questions

Does cannabis help with PTSD?
People with PTSD report using cannabis for anxiety, sleep, and other symptoms, but this review found no sufficient solid evidence from clinical trials to recommend it as a treatment.
Are medical cannabis clinics accurately representing the evidence?
This study found Polish clinics marketed cannabis as a PTSD treatment despite the weak evidence, suggesting a gap between commercial claims and scientific support.

Read the original research

Cannabis and cannabinoids in the treatment of post-traumatic stress disorder: A literature review and analysis of the content of websites of Polish clinics specializing in medical marijuana treatment.

Psychiatria polska, 59(4), 577-596

Citation

Kurowska, Patrycja; Wojtyła, Cezary; Królak, Anna; Ostrowski, Janusz; Giermaziak, Wojciech. (2025). Cannabis and cannabinoids in the treatment of post-traumatic stress disorder: A literature review and analysis of the content of websites of Polish clinics specializing in medical marijuana treatment.. Psychiatria polska, 59(4), 577-596. https://doi.org/10.12740/PP/192416

Explore the wider topic